T Cell Tolerance to Tumors and Cancer Immunotherapy
It is widely recognized that the immune system plays a role in cancer progression and that some tumors are inherently immunogenic. The identification of tumor-associated antigens (TAAs) has stimulated research focused on immunotherapies to mediate the regression of established tumors. Cancer-specific immunity has traditionally been aimed at activating CD8+ cytotoxic T lymphocytes (CTLs) directed against major histocompatibility complex (MHC) class I-binding peptide epitopes. Other approaches utilize T cell adoptive therapy where autologous, tumor-specific T cells propagated in vitro are transferred back into recipients. However, these strategies have met with limited success in part due to the regulatory mechanisms of T cell tolerance, which poses a considerable challenge to cancer immunotherapy. Our laboratory utilizes the TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model, a murine model of prostate cancer, to study mechanisms of T cell tolerization to tumor antigens. We previously demonstrated that upon encounter with their cognate antigen in the tumor microenvironment, naïve T cell become tolerized. Our ongoing studies are testing whether provision of CD4+ T cells can enhance tumor immunity by preventing CD8+ T cell tolerance. A greater understanding of the interaction between various tumor-specific T cell subsets will facilitate the design of novel approaches to stimulate a more potent antitumor immune response.
KeywordsMajor Histocompatibility Complex Tumor Antigen Cancer Immunotherapy Antitumor Immune Response Tumor Immunity
Unable to display preview. Download preview PDF.
- Attia, P., Phan, G., Maker, A., Robinson, M.,Quezado, M., Yang, J., Sherry, R., Topalian, S., Kammula, U., Royal, R., Restifo, N., Haworth, L., Levy, C., Mavroukakis, S., Nichol, G., Yellin, M. and Rosenberg, S. (2005b) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23, 6043–6053.CrossRefPubMedGoogle Scholar
- Berkow, R. and Beers, M. (1997). Cancer and the immune system. The Merck Manual of Medical Information. Whitehouse Station, Merck Research Laboratories:792–794.Google Scholar
- Comes, A., Rosso, O., Orengo, A., Carlo, E.D., Sorrentino, C., Meazza, R., Piazza, T., Valzasina, B., Nanni, P., Colombo, M. and Ferrini, S. (2006) CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. J Immunol 176, 1750–1758.PubMedGoogle Scholar
- Conejo-Garcia, J., Benencia, F., Courreges, M., Kang, E., Mohamed-Hadley, A., Buckanovich, R., Holtz, D., Jenkins, A., Na, H., Wagner, D., Katsaros, D., Caroll, R. and Coukos, G. (2004) Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 10, 950–958.CrossRefPubMedGoogle Scholar
- Curiel, T., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J., Zhang, L., Burow, M., Zhu, Y., Wei, S., Kryczek, I., Daniel, B., Gordon, A., Myers, L., Lackner, A., Disis, M., Knutson, K., Chen, L. and Zou, W. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10, 942–949.CrossRefPubMedGoogle Scholar
- Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S. and Carbone, D. (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150–4166.PubMedGoogle Scholar
- Gattinoni, L., Klebanoff, C., Palmer, D., Wrzesinski, C., Kerstann, K., Yu, Z., Finkelstein, S., Theoret, M., Rosenberg, S. and Restifo, N. (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115, 1616–1626.CrossRefPubMedGoogle Scholar
- Marzo, A., Kinnear, B., Lake, R., Frelinger, J., Collins, E., Robinson, B. and Scott, B. (2000) Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol 165, 6047–6055.Google Scholar
- Moretti, S., Pinzi, C., Berti, E., Spallanzani, A., Chiarugi, A., Boddi, V., Reali, U. and Giannotti, B. (1997) In situ expression of transforming growthfactor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 7, 313–321.CrossRefPubMedGoogle Scholar
- Overwijk, W., Lee, D., Surman, D., Irvine, K., Touloukian, C., Chan, C., Carroll, M., Moss, B., Rosenberg, S. and Restifo, N. (1999) Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4( + ) T lymphocytes. Proc Natl Acad Sci USA 96, 2982–2987.CrossRefPubMedGoogle Scholar
- Sotomayor, E., Borrello, I., Rattis, F., Cuenca, A., Abrams, J., Staveley-O’Carroll, K. and Levitsky, H. (2001) Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T cell tolerance during B-cell lymphoma progression. Blood 98, 1070–1077.CrossRefPubMedGoogle Scholar
- Sutmuller, R., Duivenvoorde, L.v., Elsas, A.v., Schumacher, T., Wildenberg, M., Allison, J., Toes, R., Offringa, R. and Melief, C. (2001) Synergism of CTLA-4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194, 823–832.CrossRefPubMedGoogle Scholar